Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday July 9

TuPeC4814 High prevalence of HIV-1 non-B subtypes
circulating in Portugal
V Dugue A Carvalho, C Morais, F Coelho,
E Rabaddo, J Oliveira, I Saraiva-da-Cunha,
A Meligo-Silvestre (Portugal)
TuPeC4815 Association between viral load and CD4 count in
HIV-1 subtype C infection in Botswana
T Peter1, V Novitsky2, S Gaolekwe, S Ahn',
A M Reich', E Sepako', H Bussmann', W Wester",
R Marlink2, I Thior', M Essex2
(Botswana; 2United States)
TuPeC4816 Spreading of a non-B subtype among IVDUs in
Switzerland
S lost, S Yerly, D Kaufmann, M Monnat, A Telenti,
J P Chave, L Kaiser, P BDrgisser, M Flepp,
P Vernazza, M Battegay, L Perrin (Switzerland)
TuPeC4817 Subtyping of recent circulating HIV-1 strains in
Cape Town, South Africa
E Janse van Rensburq, B A Robson',
F K Treurnicht, T - L Smith, CC Sampson,
E Faatz2, S Engelbrecht' (South Africa; 2Germany)
TuPeC4818 High-level exposure to nonhuman primates in
rural hunting villages in Cameroon
N D Wolfe', 1 K Carr, A T Prosser', N E MpoudP,
U Tamoufe2, N ]Torimiro2, FE McCutchan,
D L Birx, D S Burke' (United States; 2Cameroon)
TuPeC4819 Field validation of quantitation of plasma human
immunodeficiency virus type 1 (HIV-1) RNA viral
load in African adults mainly infected with
CRFo2_AG strains
FRouet, D Bonard', TA Toni, CMontcho,
A Minga, A Inwoley', C Hut, B Masquelier2,
C Rouzioux2, F Dabis2, R Salamon2
('Cote d'lvoire; 2France)
TuPeC4821 Molecular epidemiology of HIV-1 in the state of
Ceara, Northeast, Brazil
S R Gadelha, B Galvdo-Castro, N Shindo (Brazil)
TuPeC4822 HIV outbreak investigation among illicit drug
users and their contacts in Stockholm, Sweden
2001
S P E Sylvan (Sweden)
TuPeC4823 Non-B subtype strains and possible
recombinants of HIV-1 identified in a cohort of
Italian Primary HIV-1 Infections (PHIs)
L Buonaguro M Tagliamonte, M L Tornesello,
B Capiluppi, A Lazzarin, G Tambussi,
FM Buonaguro (Italy)
TuPeC4824 HTLV/STLV diversity in Gabon
M Makuwa, S Souquiere, I Bedjabaga1,
A Mouinga-Ondeme, P Telfer, F Simon2,
P Roques' (Gabon; 2France)
TuPeC4825 Genotypic variation in HIV-1 reverse transcriptase
and protease in subtype C samples from
Botswana in treated and untreated patients
P L Bollyky1, W Wester, T Peter, H Bussmann,
MI Makhema2, D Dickinson, VA Notitsky,
M Essex'( United States; 2Botswana)
TuPeC4826 HIV-i subtyping: the development of a national
surveillance system and clinical service
L E Sha, D Yirrell, S Cameron, S Burns,
G Codere, A Taylor, D ]Goldberg
(United Kingdom)
TuPeC4827 Novel 2 stage method using observational
databases to compare many different drug
combinations for HAART naive patients, in order
to find the most effective first line treatment
M N Morphet (Australia)

TuPeC4828 HIV surveillance among sentinel populations in
Europe: comparability and interpretation of
trends
A M Downs H Pilkington, F F Hamers (France)
TuPeC4829 Evaluating the effectiveness of genotypic
resistance testing in routine practice
A M Bayoumi, C Goia, S Gardner, C Major,
M Millson, G Robinson, R S Remis, A Rachlis
(Canada)
TuPeC483o Triangulation of biologic, behavioral, and
sociodemographic information as a methodological
strategy to monitor HIV trends among injection
drug users (IDUs) in Santos Metropolitan Area (SM)
and Rio de Janeiro (RJ), Brazil
D P Triqueiros', A Krall2, F C Mesquitao', PR Telles',
R C Bueno, M Hacker', F I Bastos'
(Brazil; 2United States)
TuPeC4831 Assessing the impact of environmental-structural
interventions
E Roca', K Ashburn', L Moreno2, H ]erez2,
S Rosario2, B Gomez2, M Sweat', D Kerrigan'
(United States; 2Dominican Republic)
TuPeC4832 Reduction in HIV incidence associated with
needle exchange program attendance in
Baltimore, MD; 1994-2000
F Constantine, D Scharfstein, S A Strathdee,
M Safaiean, R Varadhan, R Brookmeyer, D Vlahov
(United States)
TuPeC4833 Evaluating HIV vaccination strategies: vaccination Tuesday
policy is a critical determinant in achieving
optimal control of HIV transmission
D C Barth-Jones, I M Longini, M L Ackers,
T D Mastro (United States)
TuPeC4834 Appropriate controls in microbicide efficacy trials:
the continuing search
Z Stein, M Susser, L Myer (United States)
TuPeC4835 Changes in willingness to participate in HIV
vaccine trials among injection drug users
LA Purvis E T Golub, M Sapun, M Safaeian,
C Beyrer, W Tun, D Vlahov, S A Strathdee
(United States)
TuPeC4836 Phase II microbicide trial participants' opinions
about phase Ill trial methodology
I H H van de Wilgert', H Jones', A Pistorius2,
A de Kock2, M Sebola2, B Friedland', N Coetzee2,
A Hoosen2 (United States; 2South Africa)
TuPeC4837 Identifying a possible HIV vaccine testing site
I G Kublin', W C Miller, C S Jere', J E Chisi',
IF Hoffman', B Mbewe', R Pendame'
Malawi,; 2United States)
TuPeC4838 25 Years of HIV and AIDS in New York City:
surveillance trends
P Thomas D Nash, L Torian, S Forlenza, J Fordyce,
V Peters, L jones, Sackoff, T P Singh, I Weisfuse,
B Mojica (United States)
TuPeC4839 Data management and monitoring of trial
conduct in the first phase Ill efficacy trial of a
preventive HIV-i vaccine (AIDSVAX~ B/B) in North
America and Europe
V Gulati P Orozco-Cronin, K Green, K Orelind,
I Young, V Popovic (United States)
TuPeC484o A centralized database system for the
management and processing of HIV-related
information
R Boulme, D Gonzalez, I Robert, A M Ternes,
I C Schmit (Luxembourg)

XIV International AIDS Conference BARCELONA - JULY 7-12

lo9